A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday.
A combination of AstraZeneca’s Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday.
AstraZeneca …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
AstraZeneca, Daiichi Sankyo and Gilead report promising trial results in ‘triple negative’ breast cancer
It is estimated that 1,250 people a year could benefit from the new drug
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
